NIH Discusses How Rare Advocacy Groups Can Fund Research and Answers More Questions

Following Rare Disease Day at the NIH Clinical Center in early March, we spoke to the NIH about remaining questions we had pertaining to rare disease research. We are impressed with the work they have in place, and want to help patients and advocates better navigate their initiatives and get involved.

We asked how the NIH prioritizes research funding, how advocacy groups can fund researchers at the NIH, how the NIH supports innovative tactics, and where we could find a list of initiatives where the NIH worked with academia to advance the field of rare disease.

Yesterday, we shared the first part of this exchange, which was focused on funding prioritization. You can check out that article here.

Next, we asked about how advocacy groups funding research can collaborate with the NIH. We wanted to know what process is currently in place, and if it would be feasible for advocacy groups to fund a full-time researcher or even an entire research team, and ensure the allocation of NIH space and equipment.

The NIH answered that each of the NIH Institutes and Centers (IC) has the power to establish its own research agenda and funding priorities. However, groups hoping to fund more research are in luck– NIH confirmed that additional research may be conducted with outside funding, although they don’t solicit outside funding.

The NIH shared that they are authorized to receive gifts both directly and through the not-for-profit charitable organization, Foundation for the National Institutes of Health (FNIH). FNIH was created 28 years ago by Congress to help raise private funds, and establish public private partnerships that assist the NIH’s mission. 
There are also various ways that patient support groups and other groups with similar goals can work together on rare disease initiatives. Below are a list of National Center for Advancing Translational Sciences (NCATS) examples, compiled by the NIH:
  • Bridging Interventional Development Gaps (BrIDGs): This NCATS program supports targeted contract access to drug development resources that enable academic, not-for-profit and small business collaborators to generate the data they need to submit an Investigational New Drug application to the U.S. Food and Drug Administration.
  • Genetic and Rare Diseases Information Center (GARD): The GARD website and staff provide comprehensive information on rare and genetic diseases for patients, their families, health care providers and the public. NCATS administers GARD in collaboration with the NIH’s National Human Genome Research Institute.
  • Rare Diseases Clinical Research Network (RDCRN): This NCATS program is designed to advance medical research on rare diseases by providing support for clinical studies and facilitating collaboration, study enrollment and data sharing. Through the RDCRN consortia, physician scientists and their multidisciplinary teams work together with patient advocacy groups to study more than 200 rare diseases at sites across the nation.
  • Therapeutics for Rare and Neglected Diseases (TRND): Through this program, NCATS supports research collaborations among NIH and academic scientists, patient organizations and biopharmaceutical companies to encourage and speed the discovery of new drugs for rare and neglected diseases.

Another resource is NIH’s Clinical Trials and You initiative here.

In addition to the variety of research-related programs and grants we’ve discussed, the NIH touched on the tactics they use to support “outside-of-the-box” thinking in regards to NIH or NCATS initiatives. They specifically highlighted the work supported by the NIH Common Fund regarding undiagnosed disease. They help fund Undiagnosed Diseases Network, which is “a research study to improve and accelerate diagnosis of rare and undiagnosed conditions through both basic and clinical research.”
We also wanted to know where our readers could go to find a comprehensive list of NIH initiatives with academia, as it relates to rare disease.
The NIH responded with a fantastic resource– the NIH Estimates of Funding for Various Research, Condition, and Disease Categories (RCDC)— which provides accessible information for those interested in the current state of research for different disease states. Some rare diseases, such as Rett syndrome and Scleroderma, are listed as their own category in this tool, and others fall into the category of “Rare Diseases.”
If you click the link of the funding number on a specific fiscal year, you can see a page that shows all the projects that were funded in that year. However, since the NIH funds thousands of project, updating this system is a time-consuming process. 2017 updates are still in progress.
A little clicking around on this resource can help show what research funding proposals have been successful, and where centers for rare research are. It also shows where research funding has increased, decreased, or stayed the same over the last few years. We found that rare disease funding has substantially increased in recent years.
The NIH has provided so much great work that has saved and changed the lives of countless rare patients. As we move forward in the field of rare research, it’s vital that advocacy groups and NIH researchers are able to work together. These resources can help guide groups and individuals setting out on that path.

Share this post

Share on facebook
Share on google
Share on twitter
Share on linkedin
Share on pinterest
Share on print
Share on email
Close Menu